# Cone-Specific Filter-Based Neuromodulation: A Proposed Clinical Framework for Amblyopia, Strabismus, and ADHD

## TL;DR

This paper proposes a new clinical framework for using light filters to selectively stimulate different types of retinal cones to treat eye conditions and ADHD.

## Contribution

A standardized protocol for cone-specific neuromodulation is proposed, integrating optical parameters and safety standards for specific clinical applications.

## Key findings

- Eleven monochromatic and six combined filters were classified for targeted cone stimulation.
- The framework integrates safety and neurophysiological evidence for amblyopia, strabismus, and ADHD.
- The protocol provides reproducible ranges for wavelength, illuminance, and exposure timing.

## Abstract

Aim: To propose a standardized clinical protocol for cone-specific neuromodulation that classifies therapeutic filters for selective stimulation of S-, M-, and L-cones and translates optical and safety parameters into condition-specific frameworks for amblyopia, strabismus, and ADHD. Methods: Previously characterized spectral filters were re-evaluated using published transmittance and cone-excitation data to identify a reduced set of monochromatic and combined options with meaningful cone bias. These were integrated with α-opic metrology, international photobiological and flicker standards, and condition-specific neurophysiological evidence to define reproducible ranges for wavelength, corneal illuminance, exposure timing, temporal modulation, and safety verification. Results: The protocol consolidates eleven monochromatic and six combined filters into operational classes mapped onto mechanistic profiles for amblyopia, esotropia, exotropia, vertical deviations, and exploratory ADHD applications. All time frames and applications are presented as methodological anchors rather than efficacy claims. Conclusions: This work provides a structured, safety-anchored framework intended to guide protocol design and comparability in future cone-specific neuromodulation trials; therapeutic benefit must be demonstrated in prospective clinical studies.